Compare BioNTech SE - ADR (BNTX) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Microsoft — how do they compare? BioNTech SE - ADR trades at $90.22 (market cap $22.86B), while Microsoft trades at $397.32 (market cap $2.86T). The key difference: Microsoft is far larger — about 125.1× BioNTech SE - ADR's market cap, and Microsoft pays a 0.95% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | MSFT | |
|---|---|---|
Market Cap | $22.86B | $2.86T |
Sector | Health | Technology |
52-Week High | $119.34 | $542.07 |
52-Week Low | $83.89 | $352.83 |
Enterprise Value | $6.53B | $2.84T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Microsoft (MSFT) trades at $397.36, up 1.63% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue grew to $281.72B in 2025, and net income reached $101.83B. Analyst consensus is strongly bullish with an 80.49% buy rating and a $551.62 price target. Recent news highlights AI leadership and Azure growth, though concerns over capital expenditures persist.
Outlook: MSFT's AI integration and cloud dominance support long-term growth, but high valuation and spending fears pose risks. The stock offers upside to analyst targets, yet investors face volatility from tech sector rotation and macroeconomic pressures. Balanced view: fundamentals justify holding, but entry near support levels may reduce risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
